In relation to the treatment used, in our study, most cases received PD-1/PD-L1 inhibitor regimens in monotherapy or in combination, the latter regimen being the most frequently associated with the development of DM-ICIs [8, 22]. This evidence concerns the gene CD274 and diabetes mellitus.